Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MOLNUPIRAVIR Cause Product prescribing issue? 110 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 110 reports of Product prescribing issue have been filed in association with MOLNUPIRAVIR (LAGEVRIO). This represents 2.3% of all adverse event reports for MOLNUPIRAVIR.

110
Reports of Product prescribing issue with MOLNUPIRAVIR
2.3%
of all MOLNUPIRAVIR reports
0
Deaths
2
Hospitalizations

How Dangerous Is Product prescribing issue From MOLNUPIRAVIR?

Of the 110 reports, 2 (1.8%) required hospitalization.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MOLNUPIRAVIR. However, 110 reports have been filed with the FAERS database.

What Other Side Effects Does MOLNUPIRAVIR Cause?

Product use issue (706) No adverse event (614) Covid-19 (396) Wrong technique in product usage process (380) Product use in unapproved indication (296) Diarrhoea (259) Accidental underdose (207) Product use complaint (206) Rash (200) Underdose (183)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) LENALIDOMIDE (948) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294)

Which MOLNUPIRAVIR Alternatives Have Lower Product prescribing issue Risk?

MOLNUPIRAVIR vs MOLSIDOMINE MOLNUPIRAVIR vs MOMELOTINIB MOLNUPIRAVIR vs MOMETASONE MOLNUPIRAVIR vs MOMETASONE FUROATE MOLNUPIRAVIR vs MOMETASONE FUROATE\OLOPATADINE

Related Pages

MOLNUPIRAVIR Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue MOLNUPIRAVIR Demographics